Floatz logo

DENTALFLUORO

Hereditary Leiomyomatosis and Renal Cell Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Hereditary Leiomyomatosis and Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Pamiparib
Jonsson Comprehensive Cancer Center
Phase 2CCC
Metformin
National Cancer Institute (NCI)
Phase 1/2CCC
Zactima
National Cancer Institute (NCI)
Phase 1/2CCC
Lactate
University of Texas Southwestern Medical Center
N/AD

View all 9 →

Same molecule, other indications

DENTALFLUORO is also rated in:

metastatic carcinoma in the boneDormant
BB
Indicative ·
66 / 100
View asset →
Bone Metastases From Breast or Prostate CancerDormant
B
Indicative ·
63 / 100
View asset →
prostate neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →